POLYCYTHEMIA MARKET SIZE, SHARE, AND GROWTH: FORECASTING TRENDS AND COMPETITIVE DYNAMICS

Polycythemia Market Size, Share, and Growth: Forecasting Trends and Competitive Dynamics

Polycythemia Market Size, Share, and Growth: Forecasting Trends and Competitive Dynamics

Blog Article

Polycythemia Vera Market: Emerging Trends and Recent Developments

Polycythemia Vera (PV) is a rare hematologic disorder characterized by the overproduction of red blood cells, leading to increased blood viscosity and a heightened risk of thrombosis. The global market for PV treatments has witnessed significant growth, driven by advancements in therapeutic options and a deeper understanding of the disease's pathophysiology.​

Market Growth and Projections

Recent analyses highlight the robust expansion of the PV market. DelveInsight estimates that the Polycythemia Vera market across the seven major markets (7MM) will grow from USD 1.9 billion in 2024 to approximately USD 79.0 billion by 2035, reflecting a compound annual growth rate (CAGR) of 13.63% during this period. ​

Advancements in Therapeutic Options

The treatment landscape for PV has evolved with the introduction of novel therapies:​


  • Rusfertide: Protagonist Therapeutics, in collaboration with Takeda, reported positive topline results from the Phase 3 VERIFY study of rusfertide. The study met its primary endpoint, demonstrating a significantly higher proportion of clinical responders on rusfertide compared to placebo. Rusfertide was generally well-tolerated, with no new safety findings observed. ​


  • Sapablursen: Ionis Pharmaceuticals and Ono Pharmaceutical Co. have entered into a global license agreement granting Ono exclusive rights to develop and commercialize sapablursen, an investigational RNA-targeted medicine for PV. This collaboration aims to bring innovative treatment options to PV patients.

  • BESREMi: BESREMi has achieved strong market growth, driven by rising demand for PV treatments. The drug, along with JAKAFI, is among the FDA-approved therapies for PV, offering patients effective management options. ​


 

Incyte's Market Position

Incyte's JAKAFI has been a cornerstone in PV management. In October 2024, Incyte raised its annual sales forecast for JAKAFI, anticipating sales between $2.74 billion and $2.77 billion for the year. This adjustment reflects strong uptake among PV patients and underscores the drug's pivotal role in PV therapy.

Competitive Landscape

USA PV market is witnessing increased competition, with several companies advancing their pipeline therapies:​

  • Rusfertide: Protagonist Therapeutics and Takeda's rusfertide shows promise as a first-in-class erythrocytosis-specific agent, potentially addressing unmet medical needs in PV patients. ​P

  • Divesiran: Silence Therapeutics' divesiran is in a Phase 1/2 study named Sanreco, which demonstrated promising phlebotomy reduction in its Phase 1 portion. The study has progressed to Phase 2, with full enrollment expected by year-end.


Market Challenges and Opportunities

Despite advancements, challenges persist in the PV market:​

  • Market Size Estimation: Determining the precise market size remains complex. PV affects approximately 100,000 patients in the U.S., with estimates suggesting peak sales of rusfertide could reach $2 billion. ​

  • Treatment Accessibility: Ensuring equitable access to emerging therapies across different regions, including emerging markets like India, is crucial. This requires collaboration among pharmaceutical companies, healthcare providers, and policymakers.


Browse More Reports:

Laboratory Centrifuge Market

MEK Inhibitors Market

Safety Syringe Market

Sedimentation and Centrifugation Market

Medical X Ray Generator Market

 

Report this page